Construction of an effective M1GS ribozyme targeting HCMV UL97 mRNA segment in vitro

Acta Genetica Sinica

Volumn 32, Issue 11, 2005, Pages 1205-1212

  Zhang, Wen Jun ^a   Li, Hong Jian ^a   Li, Yue Qin ^a   He, Hua Kun ^a   Tang, Dong Sheng ^a   Zhang, Xin ^a   Zhou, Tian Hong ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

HCMV; M1GS; Ribonuclease P (RNase P); UL97

Indexed keywords

MESSENGER RNA; PROTEIN KINASE; PROTEIN SUBUNIT; RIBONUCLEASE P; RIBOZYME; ESCHERICHIA COLI PROTEIN; GANCICLOVIR KINASE; GUIDE RNA; PHOSPHOTRANSFERASE; RIBONUCLEASE P, E COLI; VIRUS RNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; COVALENT BOND; ENZYME ENGINEERING; ESCHERICHIA COLI; GENE MUTATION; GENE TARGETING; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE SEQUENCE; RNA SEQUENCE; VIRAL GENETICS; 5' UNTRANSLATED REGION; GENETICS; METABOLISM; SYNTHESIS;

ESCHERICHIA COLI; HUMAN HERPESVIRUS 5;

5' UNTRANSLATED REGIONS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEASE P; RNA, CATALYTIC; RNA, GUIDE; RNA, VIRAL;

EID: 28644443210     PISSN: 03794172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Numazaki K, Asanuma H, Chiba S. Latent infection and reactivation of human cytomegalovirus. Human Immunology Volume, 2004, 5: 403-408.
2. Revello, Maria G, Gerna G. Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. Journal of Clinical Virology, 2004, 29(2): 71-83.
3. Palella F J, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl J Med, 1998, 338: 853-860.
4. Fowler K B, Stagno S, Pass R F, Britt W J, Boll T J, Alford C A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New Engl J Med, 1992, 326: 663-667.
5. Jacobson M A, Drew W L, Feinberg J, O'Donnell J J, Whitmore P V, Miner R D, Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis, 1991, 163: 1348-1351.
6. Azad R F, Brown-Driver V, Buckheit R W, Anderson K P. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antivir Res, 1995, 28: 101-111.
7. Baldanti F, Underwood M R, Stanat S C, Biron K K, Chou S, Sarasini A. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three doubleresistant human cytomegalovirus strains recovered from patients with AIDS. J Virol, 1996, 70: 1390-1395.
8. Drew W L. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. J Acq Immune Def Synd, 1991, 4(Suppl 1): S42-S46.
9. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Prog Nucleic Acid Res Mol Biol, 1998, 58: 1-39.
10. Server N, Cantin E M, Chang P S, Zaia J A, Ladne P A, Stephens D A, Rossi J J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science, 1990, 247: 1222-1225.
11. Gervaix A, Li X, Kraus G F. Wong-Staal, Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol, 1997, 71: 3048-3053.
12. Kuwabara T, Amontov S V, Warashina M, Ohkawa J, Taira K. Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes. Nucleic Acids Res, 1996, 24: 2302-2310.
13. LIU Ge, CHEN Ya-Wen, ZHAO Xi-Lin, DONG Yuan-Shu, CHEN De-Feng. Ribozyme targeted the point mutation of activated oncogene inhibits its expression in vivo. Acta Genetics Sinica, 1996, 23(6): 477-485.
14. Ruffner D E, Stormo G D, Uhlenbeck O C. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry, 1990, 29: 10695-10702.
15. Altman S, Kirsebom L, Talbot S J. Recent studies of RNase. PFASEB J, 1993, 7: 7-15.
16. Liu F, Altman S. The differential evolution of substrates for an RNA enzyme in the presence and absence of its protein cofactor. Cell, 1994, 77: 1083-1100.
17. Yuan Y, Altman S. Selection of guide sequences that direct efficient cleavage of mRNA by human ribonuclease P. Science, 1994, 263: 1269-1273.
18. Yuan Y, Altman S. Substrate recognition by human RNase P: Identification of small, model substrates for the enzyme. EMBO J, 1995, 14: 159-168.
19. Yuan Y, Hwang E, Altman S. Targeted cleavage of mRNA by human RNase P. Proc Natl Acad Sci USA, 1992, 89: 8006-8010.
20. Eric L C, Nathan H Z, Nicholas M K, Michael E H. Analysis of substrate recognition by the ribonucleoprotein endonucleases RNase P. Methods, 2002, 26: 307-322.
21. Kim S, Kim H, Park I, Lee Y. Mutation analysis of RNA structures and sequences postulated to affect 3′ processing of M1 RNA, the RNA component of Escherichia coli RNase P. J Biol Chem, 1996, 271(32): 19330-19337.
22. Liu F, Altman S. Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli. Genes Dev, 1995, 9: 471-480.
23. Trang P, Kilani A F, Kim J, Liu F. A ribozyme derived from the catalytic subunit of RNase P from Escherichia coli is highly effective in inhibiting replication of herpes simplex virus 1. J Mol Biol, 2000, 301: 817-826.
24. Dana G W, Charmain T C, Mark N P, Edward S M. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci USA, 2001, 98: 1982-1900.
25. HE Hua-Kun, LI Yue-Qin, WANG Bo, ZHANG Wen-Jun, SU Yun-Zhen, ZHOU Tian-Hong. In vitro studies of targeted human cytomegalovirus (HCMV) by RNase P. Chinese Journal Eugenics and Heredity, 2004; 12: 8-10.
26. Liu F, Roizman B. Characterization of the protease and other products of amino-terminus-proximal cleavage of the herpes simplex virus 1 UL26 protein. J Virol, 1993, 67: 1300-1309.
27. Phong T, Ahmed K, Jarone L, Amy H, Kwa L, Joe K, Arash N, Kihoon K, Liu F Y. RNase P ribozymes for the studies and treatment of human cytomegalovirus infections. Journal of Clinical Virology, 2002, 25: S63-S74.